You may already know about PrEP - the pill one takes to reduce the risk of acquiring HIV. But did you know there is also PEP - the post-exposure prophylaxis - that is used after one may have been exposed to the HIV virus.
This evidence brief summarises key issues and priorities for action in Europe and Central Asia on HIV testing. It is largely based on data collected in 2021 by the European Centre for Disease Prevention and Control (ECDC) to monitor implementation of the 2004 Dublin Declaration.
This evidence brief summarises key issues and priorities for action in Europe and Central Asia on PrEP. It is largely based on data collected between March and September 2021 by the European Centre for Disease Prevention and Control (ECDC) to monitor implementation of the 2004 Dublin Declaration.
This document summarises evidence from studies included in the licensing file of HPV vaccines together with postlicensure, peer-reviewed data and analysis where available. This guidance does not address the safety of HPV vaccines observed during the pre- and post-licensing period.
This report presents a comprehensive analysis of the results of a 2017 survey among men who have sex with men (MSM). Based on the responses of some 128 000 participants in Europe, it provides insights on their knowledge of HIV, viral hepatitis and sexually transmitted infections (STI), sexual behaviour, prevention needs and testing habits.
A pilot project was carried out to investigate the feasibility of HIVDR surveillance in EU/EEA countries and to make recommendations for the design and implementation of a potential future HIVDR surveillance system at the European level.